Non-neoplastic parenchymal changes in kidney cancer and post-partial nephrectomy recovery of renal function

Nonneoplastic Renal Parenchymal Changes in Renal Cell Carcinoma With Tumor Thrombus

Introduction: Renal cell carcinoma may extend into the inferior vena cava (IVC) by the tumour thrombus (TT). Renal cell carcinoma with tumour thrombus (RCC/TT) could be associated with multiple collaterals making the surgery in cases of venous involvement very complex and challenging. The pathologic findings of non-neoplastic parenchymal changes in radical nephrectomy specimens of RCC/TT have not been well described.

Methods: We conducted a retrospective study of 200 nephrectomies for RCC/TT during eight years. We only included 22 patients who had a full histopathological examination of the resected nephrectomies, including the non-neoplastic parenchymal tissues.

Results: Median tumour thrombus level was III (range: II-IV), and median tumour diameter was 9.3 (range: 4-17) cm. Clear cell RCC was the most common tumour diagnosis in this cohort. Non-neoplastic renal pathologies included: (1) Global Glomerulosclerosis (GGS) in 90.9% (1-9% GGS in 15, 10-30% GGS in 4, >30% GGS in 1); (2) Interstitial fibrosis in 90.9% (mild in nine, moderate in nine, severe in 2); (3) Acute tubular injury in 14 (63.6%) patients; (4) Chronic inflammation in 77.3% (5-25% in 10, 26-50% in 7); (5) Arteriolosclerosis in all patients (mild, moderate and severe in 12, 9 and 1 patients, respectively); (6) Arteriolosclerosis: as none in 12, mild in six, moderate in four patients; (7) Focal Segmental Glomerulosclerosis in one patient. Our findings suggest that non-neoplastic parenchymal changes occur in the presence of RCC/TT. Neither tumour extension (via T-stage) nor tumour thrombus level were associated with the degree of any of these non-neoplastic parenchymal changes.

Conclusions: Knowledge of the existence of these non-neoplastic parenchymal changes in addition to determining the tumour margin(s) will be important in caring for and early determining whether any specific medical intervention(s) to help preserve renal function in the remaining contralateral kidney becomes warranted.

More than ancillary records: clinical implications of renal pathology examination in tumor nephrectomy specimens

Background

Nephrectomy is the management of choice for the treatment of renal tumors. Surgical pathologists primarily focus on tumor diagnosis and investigations relating to prognosis or therapy. Pathological changes in non-neoplastic tissue may, however, be relevant for further management and should be thoroughly assessed.

Methods

Here, we examined the non-neoplastic renal parenchyma in 206 tumor nephrectomy specimens for the presence of glomerular, tubulo-interstitial, or vascular lesions, and correlated them with clinical parameters and outcome of renal function.

Results

We analyzed 188 malignant and 18 benign or pseudo-tumorous lesions. The most common tumor type was clear cell renal cell carcinoma (CCRCC, n = 106) followed by papillary or urothelial carcinomas (n = 25). Renal pathology examination revealed the presence of kidney disease in 39 cases (18.9%). Glomerulonephritis was found in 15 cases (7.3%), and the most frequent was IgA nephropathy (n = 6; 2.9%). Vasculitis was found in two cases (0.9%). In 15 cases we found tubulo-interstitial nephritis, and in 9 severe diabetic or hypertensive nephropathy. Partial nephrectomy was not linked to better eGFR at follow-up. Age, vascular nephropathy, glomerular scarring and interstitial fibrosis were the leading independent negative factors influencing eGFR at time of surgery, whereas proteinuria was associated with reduced eGFR at 1 year.

Conclusion

Our large study population indicates a high incidence of renal diseases potentially relevant for the postoperative management of patients with renal neoplasia. Consistent and systematic reporting of non-neoplastic renal pathology in tumor nephrectomy specimens should therefore be mandatory.

Supplementary Information

The online version contains supplementary material available at 10.1007/s40620-021-01030-0.

Organ-sparing procedures in GU cancer: part 1-organ-sparing procedures in renal and adrenal tumors: a systematic review

PURPOSE

Organ-sparing surgery (OSS) for the kidney and adrenals has emerged as the need for preservation of function is paramount in patients with poor functional reserve. As reports increasingly showed that oncological outcomes were equivalent to radical excision, elective OSS became a viable alternative in patients with otherwise normal reserve. In this review, we summarize the current knowledge of OSS for adrenal and renal tumors.

MATERIALS AND METHODS

PubMed, Web of Science and Cochrane Library Central Search were searched for recently published articles up to December 2017. The following keywords were used; "partial adrenalectomy", "adrenal sparing", "partial nephrectomy", "nephron sparing", "kidney/renal cancer".

RESULTS

Partial adrenalectomy became an attractive alternative to total adrenalectomy avoiding adrenal insufficiency. Both minimally invasive surgery and ablative techniques were increasingly reported for adrenal OSS with adequate residual adrenal function and excellent oncological outcome. Radical nephrectomy remained for many years as the gold standard of treatment for organ-confined renal cell carcinoma. As the need to reduce the impact on renal function, more conservative approaches were utilized. Soon, the non-inferiority of nephron-sparing surgery to that of radical excision became evident and elective partial nephrectomy was gaining ground as the standard of care for small renal masses in patients with normal contralateral kidneys.

CONCLUSIONS

Herein, we present a comprehensive review of the current status of OSS in renal and adrenal tumors.

Partial nephrectomy vs. radical nephrectomy for stage I renal cell carcinoma in the presence of predisposing systemic diseases for chronic kidney disease

Aim of this study is to compare the effects of partial nephrectomy (PN) and radical nephrectomy (RN) for stage I renal cell carcinoma (RCC) on renal functions in patients with diabetes mellitus (DM) and/or hypertension (HT). Charts of patients who underwent surgery for stage I RCC in our department were retrospectively reviewed and patients with DM and/or HT were enrolled. Preoperative and postoperative estimated glomerular filtration rates (eGFR) were calculated according to the Modification of Diet in Renal Disease (MDRD) formulation for both RN and PN groups. Groups were compared for patient demographics, preoperative eGFR, postoperative eGFR and ΔeGFR [(preoperative eGFR) - (postoperative eGFR)] which reflects the renal functional loss. There were 85 patients in the RN and 33 patients in the PN groups. Demographic data were similar but the patients in the PN group had smaller tumor size compared to RN group (32.2 ± 11.8 mm vs 47.1 ± 15.2 mm, p < 0.001). Preoperative eGFR did not differ between groups (75 ± 28.4 mL/min/1.73 m² vs 75.5 ± 23.8 mL/min/1.73 m² in RN and PN groups, p = 0.929). However, there were significant differences between groups in terms of postoperative eGFR (57.5 ± 21.7 mL/min/1.73 m² vs 74 ± 27.5 mL/min/1.73 m² in RN and PN groups, p < 0.001) and ΔeGFR (17.5 ± 4.2 mL/min/1.73 m² vs 1.5 ± 0.4 mL/min/1.73 m² in RN and PN groups, p < 0.001). Our findings favor the use of PN over RN for stage I RCC whenever feasible in patients with predisposing systemic diseases for chronic kidney disease for better preservation of renal functions.